Changes in RAASi dose subsequent to hyperkalemia events. Among patients on renin-angiotensin-aldosterone system inhibitor (RAASi) at (a) maximum dose and (b) submaximum dose.
Reproduced with permission from Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 suppl):S212–S220.52